PomDoctor Ltd. Unsponsored ADR (POM)
NASDAQ:POM
Top Page
PomDoctor Ltd. Unsponsored ADR
(NASDAQ:POM)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.22
▼(-28.06% Downside)
Action:UpgradedDate:01/22/26
The score is driven primarily by weak financial fundamentals (persistent losses and negative equity) and bearish technical momentum (negative MACD, price below key moving averages). Valuation impact is limited because P/E and dividend data were not provided.
Positive Factors
Insurance integration / reimbursement access
Embedding national and local insurance payment into its app/WeChat mini-program creates durable reimbursement access, improving patient affordability and retention. This structural integration raises barriers to entry, increases platform stickiness, and supports scalable, reimbursable chronic-care volumes over time.
Negative Factors
Negative equity / weak balance sheet
Negative shareholders' equity and liabilities above assets signal deep solvency risk and constrained financial flexibility. Over the medium term this raises refinancing risk, limits ability to fund R&D or M&A internally, and can force dilutive financing or asset sales to stabilize the balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Insurance integration / reimbursement access
Embedding national and local insurance payment into its app/WeChat mini-program creates durable reimbursement access, improving patient affordability and retention. This structural integration raises barriers to entry, increases platform stickiness, and supports scalable, reimbursable chronic-care volumes over time.
Read all positive factors
PomDoctor Ltd. Unsponsored ADR (POM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.76M
Dividend YieldN/A
Average Volume (3M)2.20M
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,192,310
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio14.95
Price to Book (P/B)-1.54
Price to Sales (P/S)10.17
P/FCF Ratio-215.48
Enterprise Value/Market Cap17.31
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.03
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PomDoctor Ltd. Unsponsored ADR Business Overview & Revenue Model
Company Description
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and...
How the Company Makes Money
PomDoctor generates revenue through multiple channels, primarily from the sale of its pharmaceutical products and medical devices. The company engages in direct sales to healthcare providers, hospitals, and clinics, which constitute a significant ...
PomDoctor Ltd. Unsponsored ADR Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
25
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.40B | 342.56M | 304.85M | 245.22M | 215.38M |
| Gross Profit | 26.59B | 47.69M | 38.72M | 54.86M | 52.51M |
| EBITDA | 7.63B | -24.27M | -22.99M | -3.81M | -58.58M |
| Net Income | 1.71B | -143.36M | -145.39M | -125.51M | -188.40M |
Balance Sheet | |||||
| Total Assets | 124.68B | 46.23M | 66.31M | 48.62M | 19.31M |
| Cash, Cash Equivalents and Short-Term Investments | 2.11B | 7.65M | 6.72M | 2.49M | 2.17M |
| Total Debt | 37.66B | 441.10M | 413.29M | 361.24M | 341.26M |
| Total Liabilities | 92.19B | 2.14B | 2.03B | 1.95B | 1.80B |
| Stockholders Equity | 32.48B | -2.26B | -2.12B | -1.97B | -1.85B |
Cash Flow | |||||
| Free Cash Flow | -31.00M | -16.17M | -45.91M | -22.02M | -15.68M |
| Operating Cash Flow | 5.37B | -16.13M | -45.80M | -22.02M | -15.68M |
| Investing Cash Flow | -5.51B | -33.37K | -111.89K | 0.00 | -500.00K |
| Financing Cash Flow | 1.80B | 17.02M | 50.07M | 22.49M | 5.44M |
PomDoctor Ltd. Unsponsored ADR Risk Analysis
PomDoctor Ltd. Unsponsored ADR disclosed 38 risk factors in its most recent earnings report. PomDoctor Ltd. Unsponsored ADR reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PomDoctor Ltd. Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $163.11M | -21.66 | -117.74% | ― | 30.71% | 73.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $55.41M | -5.44 | 10.54% | ― | -7.46% | 73.05% | |
41 Neutral | $38.76M | ― | 6.54% | ― | ― | ― | |
41 Neutral | $49.44M | -1.59 | -122.10% | ― | -24.81% | -5344.15% |
* Healthcare Sector Average
POM
PomDoctor Ltd. Unsponsored ADR
0.33
-3.71
-91.94%
PETS
Petmed Express
2.31
-0.82
-26.20%
YI
111
6.41
0.26
4.23%
LFMD
LifeMD
3.40
-1.58
-31.73%
PomDoctor Ltd. Unsponsored ADR Corporate Events
Pomdoctor Deepens Medical Insurance Integration to Expand Online Chronic-Care Reach Across Major Chinese Cities
Feb 4, 2026
On February 4, 2026, Pomdoctor Limited announced a strategic expansion of its integration with China’s national and local medical insurance systems across major cities, aiming to broaden market reach and enhance its online chronic-care servi...
Pomdoctor Receives Nasdaq Deficiency Notice Over Minimum Bid Price
Feb 2, 2026
On February 2, 2026, Pomdoctor Limited announced that it received a Nasdaq notice dated January 29, 2026, stating that the company’s American depositary shares had traded below the US$1.00 minimum bid price requirement for 33 consecutive bus...
Pomdoctor Deepens Pharma Partnerships to Drive Internet Hospital Expansion in China
Jan 16, 2026
On January 16, 2026, Pomdoctor Limited reported significant progress in its strategic collaborations with several leading domestic pharmaceutical companies, including Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Phar...
Pomdoctor Limited Reports Strong Revenue Growth Amidst Challenging Conditions
Dec 3, 2025
Pomdoctor Limited announced its unaudited financial results for the first half of fiscal 2025, ending June 30, 2025. Despite a challenging economic environment, the company reported a 16.2% increase in net revenue, driven by an 83.2% growth in onl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.